Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Venomil is a brand name for a line of venom immunotherapy products used to desensitize patients with severe, IgE-mediated allergic reactions to insect stings. [8, 11] These biologic products contain various sterile, freeze-dried insect venom proteins as active ingredients, such as those from honey bees, wasps, yellow jackets, and hornets. [14] Administered via a series of subcutaneous injections with gradually increasing doses, Venomil aims to modulate the patient's immune response, reducing the severity of allergic symptoms upon subsequent stings. [1, 14] The treatment is indicated for patients with a confirmed history of systemic allergic reactions and positive skin tests to specific insect venoms. [14] The product line is also used for diagnostic skin testing to identify the specific venom causing the allergy. [10, 14] The products were originally manufactured by Baxalta, which was later acquired, and are now associated with Jubilant HollisterStier. [6, 14, 15]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Venomil.